List of Excipients in Branded Drug FORTICAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	FORTICAL	calcitonin salmon	54868-5499	BENZYL ALCOHOL	1969-12-31
Physicians Total Care Inc	FORTICAL	calcitonin salmon	54868-5499	CITRIC ACID MONOHYDRATE	1969-12-31
Physicians Total Care Inc	FORTICAL	calcitonin salmon	54868-5499	HYDROCHLORIC ACID	1969-12-31
Physicians Total Care Inc	FORTICAL	calcitonin salmon	54868-5499	PHENETHYL ALCOHOL	1969-12-31
Physicians Total Care Inc	FORTICAL	calcitonin salmon	54868-5499	POLYSORBATE 80	1969-12-31
Physicians Total Care Inc	FORTICAL	calcitonin salmon	54868-5499	SODIUM CHLORIDE	1969-12-31

Fortical Excipient Strategy and Commercial Opportunities in Calcitonin Salmon Nasal Spray

Last updated: August 12, 2026

Fortical is a 200-IU-per-spray calcitonin salmon nasal spray for postmenopausal osteoporosis. Its commercial value is constrained by weak clinical demand, safety concerns involving malignancy risk, competition from generic calcitonin products, and the availability of more effective osteoporosis therapies. The main excipient opportunities are not basic reformulation alone. They are preservative-free delivery, improved nasal deposition, better peptide stability, device differentiation, and reduced local irritation.

What is Fortical and which excipients does it contain?

Fortical contains synthetic salmon calcitonin at a dose of 200 International Units per actuation. The product is administered intranasally, generally as one spray daily, with alternating nostrils recommended in the labeling.[1]

The labeled inactive ingredients include:

Excipient or component	Functional role
Benzalkonium chloride	Preservative and antimicrobial protection
Citric acid	pH adjustment and buffering
Sodium citrate	Buffering and pH control
Sodium chloride	Tonicity adjustment
Hydrochloric acid or sodium hydroxide	Final pH adjustment
Purified water	Vehicle

Fortical is supplied as a multidose nasal spray. The formulation must preserve peptide activity during storage, maintain sprayability, limit microbial growth after repeated use, and deliver a reproducible dose to the nasal mucosa.[1]

The excipient system is commercially conventional. Its main limitation is the use of benzalkonium chloride in a chronic nasal product. Benzalkonium chloride can produce local irritation and, with repeated exposure, may affect nasal epithelial integrity in some patients. That creates an opening for preservative-free or lower-preservative alternatives.

What excipient functions are most important in Fortical reformulation?

Peptide stability

Calcitonin salmon is a 32-amino-acid peptide. Its stability can be affected by pH, temperature, aggregation, adsorption to container surfaces, and repeated exposure to air during multidose use.

A commercial reformulation would need to control:

• Chemical degradation of the peptide
• Aggregation and precipitation
• Adsorption to the pump, container, or elastomeric components
• Loss of potency during in-use storage
• Dose variability near the end of the container life

Citric acid and sodium citrate provide a familiar buffer system. A reformulator could evaluate phosphate, acetate, or histidine buffers, but each alternative would require compatibility testing with calcitonin, the pump, and the nasal mucosa.

Nasal tolerability

Nasal irritation is a material product attribute for chronic use. The excipient strategy should address:

• Preservative exposure
• Osmolality
• pH
• Spray volume
• Viscosity
• Local residence time
• Ciliary function
• Burning, dryness, and congestion

A lower-irritation product could improve adherence even if it does not materially improve systemic exposure. For Fortical, tolerability may have greater commercial importance than aggressive absorption enhancement because calcitonin already has an established nasal delivery route.

Microbial control

A multidose nasal spray needs antimicrobial protection unless its container and dosing architecture eliminate repeated microbial exposure. Benzalkonium chloride is effective and familiar, but removing it requires a replacement strategy.

Potential approaches include:

1. Preservative-free unit-dose ampoules.
2. A sterile, sealed multidose pump.
3. A mechanically protected valve system.
4. Alternative preservatives with lower irritation potential.
5. A low-bioburden manufacturing process combined with a validated container-closure system.

The most commercially defensible approach is likely a preservative-free multidose system rather than a simple substitution of one preservative for another.

What formulations are protected by Fortical’s excipient profile?

The original Fortical formulation is not commercially protected merely because it contains common excipients. Patent value would depend on claim scope covering a specific combination, concentration range, stability profile, device, manufacturing process, or clinical use.

Potentially protectable formulation features include:

Patentable subject matter	Commercial relevance
Preservative-free calcitonin nasal formulation	Addresses irritation and chronic-use concerns
Defined pH and buffer range	Supports peptide stability and dose uniformity
Low-volume nasal spray	Reduces drip and improves patient acceptance
Enhanced bioavailability formulation	Could reduce dose or improve exposure
Stabilized calcitonin composition	Extends shelf life and lowers cold-chain requirements
Device-formulation combination	Creates product-level differentiation
Unit-dose container	Supports sterility and preservative-free positioning
Mucoadhesive formulation	May increase nasal residence time
Absorption-enhancer formulation	May increase systemic delivery but raises tolerability risk

A patent strategy should avoid relying on broad claims to "calcitonin plus excipients." Those claims are vulnerable to prior art and obviousness challenges. Stronger claims would link a defined formulation to measurable performance, such as retained potency after in-use storage, reduced aggregation, improved delivery, or reduced mucosal irritation.

When does Fortical lose exclusivity?

Fortical does not have the commercial exclusivity profile of a newer biologic or specialty injectable. Calcitonin salmon is a relatively old peptide active ingredient, and FDA-approved generic calcitonin salmon nasal spray products have entered the U.S. market.

FDA approval of generic calcitonin salmon nasal spray products means that a conventional Fortical formulation has limited ability to command a premium solely on the basis of the active ingredient. The commercial defense must come from one or more of the following:

• A differentiated device
• Better tolerability
• A preservative-free presentation
• Longer shelf life
• More convenient dosing
• A new indication supported by clinical evidence
• Distribution in markets with limited generic penetration

FDA's Orange Book remains the relevant source for current listed patents and exclusivity information. The principal commercial issue is that any historical Fortical formulation or method-of-use patents would not, by themselves, prevent later generic entry once their enforceable terms and regulatory protections ended.[2]

What is the Orange Book status of Fortical?

The Orange Book determines whether an NDA has listed patents that an ANDA applicant must address through a Paragraph IV certification or other patent certification.[2]

For Fortical, the relevant review should distinguish among:

• Patents covering the active ingredient
• Formulation patents
• Device or container patents
• Method-of-use patents
• Pediatric exclusivity
• Orphan-drug exclusivity
• Regulatory exclusivity unrelated to patent term

Calcitonin salmon nasal spray is not a biologic-biosimilar product in the ordinary U.S. regulatory sense. A competing product using the same active ingredient and route would generally be evaluated through the abbreviated new drug application pathway if it meets the applicable requirements, rather than through the biosimilar pathway.

Current commercial diligence should rely on the active Orange Book record and Drugs@FDA approval history, not historical patent references reproduced in secondary databases. The FDA label identifies the product's composition and use, while the Orange Book determines the regulatory patent framework.[1,2]

Which companies are challenging Fortical through generic competition?

Generic competition has come from manufacturers of calcitonin salmon nasal spray products, including products associated with Par Pharmaceutical and other generic suppliers over time. The generic market has not produced the same scale of competition seen in high-volume small-molecule medicines because the calcitonin market is comparatively small and the product has experienced declining clinical use.

The relevant competitive variables are:

Variable	Fortical position	Generic opportunity
Active ingredient	Established calcitonin salmon	Same active ingredient
Route	Nasal	Same route
Dose	200 IU per spray	Generally equivalent labeled dose
Preservative system	Conventional multidose approach	Potential cost advantage
Device	Product-specific pump	Device equivalence or redesign
Clinical demand	Limited and declining	Low-cost substitution
Safety profile	Subject to calcitonin malignancy concern	Same active-ingredient concern
Pricing	Vulnerable to generic erosion	Low-price strategy

A generic manufacturer can compete on price, but the market may not support a large number of suppliers. This creates an opportunity for a differentiated product rather than another undifferentiated generic.

What regulatory risks affect Fortical commercial opportunities?

FDA has warned that intranasal calcitonin salmon may be associated with an increased risk of malignancy. In 2014, FDA concluded that the available evidence did not support removal of the product from the U.S. market, but it required labeling that reflects the risk and the limited role of calcitonin in osteoporosis treatment.[3]

The principal regulatory constraints are:

• Calcitonin is not a first-line osteoporosis therapy.
• Other treatments, including bisphosphonates, denosumab, teriparatide, abaloparatide, and romosozumab, have stronger commercial positions.
• Long-term use is difficult to justify in many patients.
• A new formulation does not eliminate active-ingredient safety concerns.
• A preservative-free product may improve tolerability but does not create a new clinical indication.
• An absorption-enhanced product could increase systemic exposure and require additional safety assessment.

A reformulated product would likely require a 505(b)(2) application if it relies on Fortical or another approved calcitonin product while introducing meaningful formulation, device, or dosing changes. A fully equivalent product could pursue an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, quality, and device performance.[4]

What patent litigation and Paragraph IV risks exist?

Paragraph IV risk is greatest for a generic applicant that relies on an approved product while asserting that listed patents are invalid, unenforceable, or not infringed. The relevant risks include:

• A 30-month stay triggered by timely patent litigation
• Litigation over formulation claim scope
• Disputes concerning nasal pump equivalence
• Method-of-use patent disputes
• Labeling carve-out issues
• Approval delays caused by device or quality deficiencies

For a new preservative-free product, the patent risk may shift away from historical Fortical patents and toward new formulation and device patents. The product sponsor could create a fresh estate around:

• Preservative-free storage stability
• Sterile multidose delivery
• Defined peptide concentration and buffer composition
• Specific pump architecture
• Low-irritation spray characteristics
• Container-closure integrity
• Manufacturing controls for peptide adsorption and aggregation

The strongest litigation position would combine formulation claims, device claims, process claims, and clinical-use claims. A single broad formulation patent would provide a weaker barrier.

How strong is the Fortical patent estate?

The Fortical estate is commercially weaker than the patent estate of a recent branded drug because the active ingredient is old, generic competition exists, and the clinical market has contracted. The remaining value is more likely to reside in product-specific formulation, device, and manufacturing rights than in the calcitonin molecule itself.

Estate component	Relative strength	Reason
Calcitonin salmon active ingredient	Low	Established peptide and generic availability
Conventional excipients	Low	Common pharmaceutical materials
Specific formulation ranges	Moderate	Strength depends on unexpected stability or tolerability data
Nasal device	Moderate	Can create design-around and equivalence issues
Preservative-free system	Moderate to high	Stronger if linked to validated microbial and stability performance
Manufacturing process	Moderate	Valuable if it solves adsorption, aggregation, or sterility problems
Method of use	Low to moderate	Limited by narrow clinical role and safety labeling
Trademark and brand recognition	Low to moderate	Useful only in a small specialist market

What are the best commercial opportunities for Fortical excipients?

Preservative-free Fortical alternative

A preservative-free spray could target patients with chronic nasal irritation or intolerance to benzalkonium chloride. The product would need a validated multidose sterility system or unit-dose packaging.

Improved nasal pump

A pump that reduces residual volume, improves plume geometry, or provides more consistent dosing could support a premium product. Device differentiation may be easier to defend than a simple excipient substitution.

Stabilized formulation with extended shelf life

A formulation that maintains potency under more demanding storage conditions could reduce wastage and improve distribution. This opportunity is relevant in markets where pharmacy refrigeration or strict inventory controls are difficult.

Lower-irritation formulation

An optimized buffer and tonicity system could reduce burning and congestion. Commercial claims would need clinical support because in vitro pH and osmolality data alone would not establish a meaningful patient benefit.

Contract development and manufacturing

Specialty manufacturers could offer formulation development, nasal-device integration, sterile filling, and ANDA or 505(b)(2) support to companies seeking entry into low-volume peptide nasal products.

How does Fortical compare with competing osteoporosis medicines?

Fortical is disadvantaged on efficacy perception, treatment duration, and guideline positioning. Its main remaining niches are acute vertebral fracture pain in selected patients and situations where alternative therapies are unsuitable, although clinical use depends on current labeling and physician judgment.[1,3]

Product class	Delivery	Commercial position versus Fortical
Bisphosphonates	Oral or injectable	Broad first-line use and low cost
Denosumab	Injection	Strong efficacy and established specialty use
Teriparatide and abaloparatide	Injection	Anabolic therapy with higher clinical differentiation
Romosozumab	Injection	High-value specialty osteoporosis product
Calcitonin salmon	Nasal or injectable	Narrower role and greater safety scrutiny

What geographic opportunities remain?

The opportunity is strongest in markets where:

• Calcitonin remains reimbursed for limited indications.
• Generic competition is fragmented.
• Nasal delivery is preferred over injection.
• Local manufacturers lack peptide nasal-device capabilities.
• Preservative-free products command a reimbursement or pharmacy advantage.
• Regulatory pathways accept bridging to an established calcitonin product.

A U.S. launch would face generic and safety headwinds. Selected international markets may offer better pricing, but the commercial case depends on local reimbursement, labeling, patent status, and the availability of competing osteoporosis therapies.

Key Takeaways

• Fortical uses a conventional aqueous calcitonin salmon nasal spray with benzalkonium chloride, citrate buffer, sodium chloride, and water.
• The best excipient opportunity is a preservative-free or lower-irritation product supported by a differentiated multidose or unit-dose device.
• Calcitonin salmon is an old active ingredient, so molecule-level exclusivity provides little commercial protection.
• Generic entry and FDA's malignancy warning limit the value of an undifferentiated Fortical copy.
• A 505(b)(2) strategy may be appropriate for a materially improved formulation or device, while an ANDA is more suitable for a therapeutically equivalent generic.
• New patents should focus on formulation-performance relationships, device integration, manufacturing controls, and validated stability.
• The commercial market is niche and likely favors specialty distribution, licensing, or contract development over a broad primary-care launch.

FAQs

Can benzalkonium chloride be removed from Fortical?

Yes, but removal requires a validated preservative-free container-closure and dosing system, or a replacement antimicrobial strategy. The sponsor must demonstrate microbial control, stability, dose uniformity, and device compatibility.

Would a preservative-free calcitonin spray qualify for a new patent?

It could, if the claims cover a novel formulation, container, device, manufacturing process, or performance result. Preservative removal alone may face novelty and obviousness challenges without supporting technical advantages.

Is Fortical eligible for biosimilar competition?

No. Calcitonin salmon nasal spray competition is generally associated with conventional generic-drug pathways rather than the biosimilar pathway.

Could an absorption enhancer create a premium Fortical product?

Potentially, but increased exposure could introduce safety and tolerability concerns. The commercial case would require evidence of a meaningful clinical or adherence benefit.

Is a Fortical reformulation commercially attractive?

Only in a narrow strategy. The strongest rationale is a differentiated, preservative-free, better-tolerated product aimed at patients who cannot use standard osteoporosis therapies or who require a nasal calcitonin option.

References

1. U.S. Food and Drug Administration. (2017). Fortical (calcitonin salmon) nasal spray prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021200s011lbl.pdf
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2014). FDA drug safety communication: Changes to labeling for calcitonin salmon nasal spray. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-safety-information-calcitonin-salmon-nasal-spray
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/applications-covered-section-505b2